期刊文献+

血小板活化过程中膜糖蛋白Ⅱb/Ⅲa构象变化的研究 被引量:6

Study on conformational changes of GP Ⅱb/Ⅲa complex during platelet activation
原文传递
导出
摘要 目的 对血小板活化过程中膜糖蛋白( G P) Ⅱb/ Ⅲa 构象变化进行初步探讨。方法 分别用供体荧光( F I T C) 与受体荧光( T R) 标记识别 G PⅡb/ Ⅲa 上不同抗原决定簇的单抗。用流式细胞仪检测活化血小板在530 nm 处的荧光强度值,并计算荧光供受体间的荧光共振能量转移值( F R E T V) 。结果 不论何种单抗作为荧光供体,静息态血小板均可被测得一低而稳定的 F R E T V( 平均5 .5 % ) 。血小板被激活时 F R E T V 会有显著升高,表明 G PⅡb/ Ⅲa 内的亚单位间发生了位置或( 和) 方向上的变化,该变化也可因胞外钙离子的清除而发生,但不依赖于纤维蛋白原与其受体的结合。结论 血小板活化时 F R E T V 的升高可定性反映出荧光标记单抗所结合的 G PⅡb/ Ⅲa 内部亚单位间所发生的重新排列,这种构象的改变可最终导致纤维蛋白原受体的表达。 Objective To determine whether a conformational change in GPⅡb/Ⅲa occurs during platelet activation. Methods Epitopes on GPⅡb/Ⅲa complex were labeled with McAbs to GPⅡb (SZ 22) and GPⅢa (SZ 21) conjugated to either a donor fluorescein (FITC labeled) or an acceptor (TR labeled) chromophore. The FRET between platelet bound FITC and TR was measured and calculated by flow cytometry during platelet activation induced by some agonists. Results In unstimulated platelets, a small but consistent change of FRET (5.5%) was detected, regardless of which antibody served as FRET donor. Platelet activation resulted in an obvious increase in FRET, suggesting a significant change in the separation or orientation of the epitopes within GPⅡb/Ⅲa. This kind of changes could also occur on removing the extracellular calcium , and was independent of receptor occupancy. Conclusion The increase in FRET can reflect the rearrangement of the chromophore labeled McAbs bound to GPⅡb/Ⅲa during platelet activation, and this kind of structural rearrangement subunits of GPⅡb/Ⅲa complex subunits can induce fibrinogen receptor expression.
出处 《中华血液学杂志》 CAS CSCD 北大核心 1999年第9期459-461,共3页 Chinese Journal of Hematology
基金 国家自然科学基金
关键词 血小板活化 膜糖蛋白类 流式细胞术 蛋白质构象 Platelet activation Membrane glycoprotein Flow cytometry Protein conformation
  • 相关文献

参考文献1

  • 1Peng L,Thromb Res,1997年,87卷,65页

同被引文献61

  • 1顾建钧,朱爱国,吴开伦,俞信祥,顾静欣.肺源性心脏病患者血小板活化及对策[J].中国临床医学,2001,8(1):57-59. 被引量:4
  • 2吴国新,阮长耿.血小板颗粒膜蛋白研究进展[J].中华血液学杂志,1994,15(3):162-164. 被引量:231
  • 3Rabe KF,Hurd S,Anzueto A,et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease:GOLD executive summary. Am J Respir Crit Care Med, 2007,176 ( 6 ) : 532-555.
  • 4Nauser TD, Stites SW. Diagnosis and treatment of pulmonary hypertension. Am Faro Physician, 2001,63(9) : 1789-1798.
  • 5Gonzalez AM,Smith A,Emery C,et al. Pulmonary hypertension,family and environment. J Hum Hypertena, 1997,11(9) :559-561.
  • 6MacLean MR, Herve P, Eddahibi S, et al. 5-hydroxytryplamine and the puhnonary circulation:recptors,transporters and relevance to pulmonary arterial hyingtension. Br J Pharmacol,2000,131 (2): 161-168.
  • 7Michelson AD, Barnard MR, Krueger LA, et al. Evaluation of paltelet function by flow cytometry. Method ,2000, 21:259-270.
  • 8Leinoe EB, Hoffmann MH, Kjaersgaard E, et al. Prediction of haemorrhage in the early stage of acute myeloid leukaemia by flow cytemetric analysis of platelet function. Br J Haematol, 2005,128:526-532.
  • 9Leinoe EB, Hoffmann MH, Kjaersgaard E, et al. Multiple platelet defects identified by flow cytometry at diagnosis in acute myeloid leukaemia. Br J Haematol,2004,127:76-84.
  • 10Christian SL, Jan SL, Arnold GR, et al. Platelet glycoprotein expression in patients with myelodysplastic syndrome. Thromb Res, 2000,100:27-34.

引证文献6

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部